# Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac

> **NCT07457307** · PHASE1 · NOT_YET_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 20 (estimated)

## Conditions studied

- High-grade Glioma

## Interventions

- **DEVICE:** MR-Linac System
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07457307
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2029-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457307, "Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07457307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*